Weak gravitational lensing measurements based on photometry are limited by shape noise: the variance in the unknown unlensed orientations of the source galaxies. If the source is a disk galaxy with a well-ordered velocity field, however, velocity field data can support simultaneous inference of the shear, inclination, and position angle, virtually eliminating shape noise. We use the Fisher information matrix formalism to forecast the precision of this method in the idealized case of a perfectly ordered velocity field defined on an infinitesimally thin disk. For nearly face-on targets, one shear component, γ×, can be constrained to 0.003 9025/Ionpix, where I0 is the signal-to-noise ratio of the central intensity pixel and npix is the number of pixels across a diameter enclosing 80% of the light. This precision degrades with inclination angle by a factor of 3 by i = 50°. The uncertainty on the other shear component, γ+, is about 1.5 (7) times larger than the γ× uncertainty for targets at i = 10° (50°). For an arbitrary galaxy position angle on the sky, these forecasts apply not to γ+ and γ× as defined on the sky but to two eigenvectors in (γ+, γ×, μ) space, where μ is the magnification. We also forecast the potential of less expensive partial observations of the velocity field, such as slit spectroscopy. We conclude by outlining some ways in which real galaxies depart from our idealized model and thus create random or systematic uncertainties not captured here. In particular, our forecast γ× precision is currently limited only by the data quality rather than scatter in galaxy properties because the relevant type of scatter has yet to be measured.

Our understanding of the molecular mechanisms of many neurological disorders has been greatly enhanced by the discovery of mutations in genes linked to familial forms of these diseases. These have facilitated the generation of cell and animal models that can be used to understand the underlying molecular pathology. Recently, there has been a surge of interest in the use of patient-derived cells, due to the development of induced pluripotent stem cells and their subsequent differentiation into neurons and glia. Access to patient cell lines carrying the relevant mutations is a limiting factor for many centres wishing to pursue this research. We have therefore generated an open-access collection of fibroblast lines from patients carrying mutations linked to neurological disease. These cell lines have been deposited in the National Institute for Neurological Disorders and Stroke (NINDS) Repository at the Coriell Institute for Medical Research and can be requested by any research group for use in in vitro disease modelling. There are currently 71 mutation-defined cell lines available for request from a wide range of neurological disorders and this collection will be continually expanded. This represents a significant resource that will advance the use of patient cells as disease models by the scientific community.